Back to Search
JOEL PICUS, MD
MD
Medical Oncology Physician
NPI: 1932125259IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
R1P41(MO)
Education
HARVARD MEDICAL SCHOOL
Class of 1984
Research & Publications (20)
Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
PMID 19326424·Pediatr Blood Cancer·2009
8-other
Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer.
PMID 19282466·Ann Oncol·2009
8-other
A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma.
PMID 18398613·Cancer Chemother Pharmacol·2009
3-trial
Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies.
PMID 18414864·Cancer Chemother Pharmacol·2009
3-trial
Radiotherapy for epidermoid carcinoma of the anus: thirty years' experience.
PMID 19251377·Int J Radiat Oncol Biol Phys·2009
8-other
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.
PMID 18936475·J Clin Oncol·2008
3-trial
Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study.
PMID 18650621·Ann Surg·2008
3-trial
Activity of sunitinib in patients with advanced neuroendocrine tumors.
PMID 18612155·J Clin Oncol·2008
3-trial
Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies.
PMID 18534963·Ann Oncol·2008
3-trial
Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study.
PMID 18682881·Dis Colon Rectum·2008
2-rct
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.
PMID 18591556·J Clin Oncol·2008
4-observational
A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer.
PMID 17516069·Cancer Chemother Pharmacol·2008
3-trial
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study.
PMID 17437819·J Urol·2007
3-trial
Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors.
PMID 17449759·AJR Am J Roentgenol·2007
8-other
Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel.
PMID 17618407·Invest New Drugs·2007
3-trial
Phase II study of erlotinib in patients with advanced biliary cancer.
PMID 16809731·J Clin Oncol·2006
3-trial
The role of primary chemotherapy for prostate cancer: has the time come?
PMID 16630527·Curr Urol Rep·2006
6-review
Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480.
PMID 16729910·Clin Genitourin Cancer·2006
8-other
A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008.
PMID 16909426·Cancer·2006
3-trial
Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.
PMID 16170173·J Clin Oncol·2005
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 4921 PARKVIEW PL, DIV IM MEDICAL ONCOLOGY, STE 7A, 7B, 7C
SAINT LOUIS, MO 63110 - Phone
- (800) 647-2098
Quick Facts
- NPI
- 1932125259
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 42
- Publications
- 20
Are you this provider?
Claim Your Profile